Vitamin K antagonist reversal strategies: Systematic review and network meta-analysis from the AABB

Pagano M. B., Foroutan F., Goel R., Allen E. S., Cushing M. M., Garcia D. A., ...More

Transfusion, vol.62, no.8, pp.1652-1661, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 62 Issue: 8
  • Publication Date: 2022
  • Doi Number: 10.1111/trf.17010
  • Journal Name: Transfusion
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, BIOSIS, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.1652-1661
  • Keywords: anticoagulation, prothrombin complex concentrate, warfarin
  • TED University Affiliated: No


© 2022 AABB.Background: Anticoagulation requires urgent reversal in cases of life-threatening bleeding or invasive procedures. Study Design and Methods: Network meta-analysis for comparing the safety and efficacy of warfarin reversal strategies including plasma and prothrombin complex concentrates (PCCs). Results: Seven studies including 594 subjects using reversal agents plasma, 3-factor-PCC (Uman Complex and Konyne), and 4-factor-PCC (Beriplex/KCentra, Octaplex, and Cofact) met inclusion criteria. Compared with plasma, patients receiving Cofact probably have a higher rate of international normalized ratio (INR) correction (risk difference [RD] 499 more per 1000 patients, 95% confidence interval [CI], 176–761, low certainty[LC]); higher reversal of bleeding (323 more per 1000 patients, 11–344 more, LC); and fewer transfusion requirements (0.96 fewer units, 1.65–0.27 fewer, LC). Patients receiving Beriplex/KCentra probably have a higher rate of INR correction (476 more per 1000 patients, 332–609 more, LC); higher reversal of bleeding (127 more per 1000 patients, 43 fewer to 236 more); and similar transfusion requirements (0.01 fewer units, 0.31 fewer to 0.28 more, high/moderate certainty). Patients receiving Octaplex probably have a higher rate of INR correction (RD 579 more per 1000 patients, 189–825 more, LC). Conclusions: PCCs probably provide an advantage in INR reversal compared to plasma. There was no added risk of adverse events with PCCs.